Merck & Co., Inc. (NYSE:MRK) Stock Gets Price Target Cut from Royal Bank Of Canada

Merck & Co., Inc. (NYSE:MRK) had its target price lowered by Royal Bank Of Canada from $150.00 to $145.00 in a research note published on Monday morning,Benzinga reports. The firm currently has a sector perform rating on the stock.

MRK has been the topic of a number of other research reports. Guggenheim upped their target price on Merck & Co., Inc. from $146.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday, September 8th. Wolfe Research lifted their price objective on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a research note on Tuesday, August 25th. Cantor Fitzgerald lifted their price objective on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. Leerink Partners upped their price objective on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Finally, Argus upped their price objective on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. Seventeen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus price target of $151.92.

Merck & Co., Inc. Stock Up 3.9%

MRK stock opened at $147.47 on Monday. The firm has a 50 day moving average of $144.91 and a 200 day moving average of $128.93. The stock has a market capitalization of $363.83 billion, a PE ratio of 117.97, a price-to-earnings-growth ratio of 6.56 and a beta of 0.21. Merck & Co., Inc. has a 52 week low of $82.01 and a 52 week high of $156.92. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same period in the previous year, the firm posted $2.13 earnings per share. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Sell-side analysts forecast that Merck & Co., Inc. will post 2.66 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were given a dividend of $0.85 per share. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

Insider Activity

In related news, EVP Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the transaction, the executive vice president owned 36,613 shares in the company, valued at $4,942,755. The trade was a 21.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the company’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the transaction, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. The trade was a 63.83% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is currently owned by corporate insiders.

Institutional Trading of Merck & Co., Inc.

A number of institutional investors and hedge funds have recently made changes to their positions in MRK. West Wealth Group LLC grew its position in shares of Merck & Co., Inc. by 28.4% in the third quarter. West Wealth Group LLC now owns 2,097 shares of the company’s stock valued at $305,000 after purchasing an additional 464 shares during the period. First Pacific Financial increased its stake in Merck & Co., Inc. by 4.5% in the third quarter. First Pacific Financial now owns 43,248 shares of the company’s stock valued at $6,284,000 after purchasing an additional 1,869 shares during the last quarter. Reliant Investment Management LLC purchased a new position in Merck & Co., Inc. during the third quarter worth about $303,000. Strategy Asset Managers LLC lifted its position in Merck & Co., Inc. by 31.9% during the third quarter. Strategy Asset Managers LLC now owns 48,703 shares of the company’s stock worth $7,077,000 after buying an additional 11,779 shares during the period. Finally, Johnson Bixby & Associates LLC lifted its position in Merck & Co., Inc. by 3.9% during the third quarter. Johnson Bixby & Associates LLC now owns 4,415 shares of the company’s stock worth $642,000 after buying an additional 166 shares during the period. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Keytruda and pipeline catalysts support Q3 optimism. Continued Keytruda sales growth, expanded indications and newer launches could help Merck exceed third-quarter expectations. Will Keytruda Continue to Aid Merck’s Top Line in Q3 Earnings?
• Positive Sentiment: Oncology pipeline data is an important longer-term catalyst. Merck plans to present first-time pivotal Phase 3 results from three studies and more than 90 additional abstracts at ESMO 2026, potentially providing evidence of growth opportunities as Keytruda eventually faces biosimilar pressure. Merck ESMO 2026 Oncology Pipeline Announcement
• Positive Sentiment: Management sounded constructive on the Moderna cancer vaccine partnership. CEO Rob Davis said manufacturing of the personalized cancer vaccine should become faster and more efficient as Merck and Moderna refine the complex production process. Merck CEO Discusses Cancer Vaccine Manufacturing
• Positive Sentiment: Leerink Partners initiated or reiterated a Buy rating on Merck, adding favorable analyst sentiment. Merck Gets a Buy Rating from Leerink Partners

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.